67 FR 95 pg. 34913 - Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Assay for the Proteolytic Activity of Serotype A Neurotoxin From Clostridium Botulinum
Type: NOTICEVolume: 67Number: 95Page: 34913
FR document: [FR Doc. 02-12181 Filed 5-15-02; 8:45 am]
Agency: Defense Department
Sub Agency: Department of the Army
Official PDF Version: PDF Version
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Assay for the Proteolytic Activity of Serotype A Neurotoxin From Clostridium Botulinum
AGENCY:
Department of the Army, DOD.
ACTION:
Notice.
SUMMARY:
In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent No. 5,965,699 entitled "Assay for the Proteolytic Activity of Serotype A Neurotoxin from Clostridium Botulinum" issued October 12, 1999. The United States Government, as represented by the Secretary of the Army has rights in this invention.
ADDRESSES:
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION:
A label-based assay is described , through modifications of substrate structure and derivatization of serum albumin, which can be used to determine type A proteolytic activity without separation of products.
Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-12181 Filed 5-15-02; 8:45 am]
BILLING CODE 3710-08-M